ArticleFrontiers in pharmacology2026

Optimizing PD-1/PD-L1 inhibitors plus chemotherapy for driver mutation-negative non-squamous NSCLC in China: a cost-effectiveness analysis.

Jianwei Ji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.